Driven by growth in its pharmaceutical and healthcare businesses, Yuhan Corporation saw increases in both revenue and operating profit in the third quarter. In particular, operating profit rose by more than 50% compared to the same period last year, demonstrating a clear improvement in profitability.
On the 28th, Yuhan Corporation disclosed that it recorded consolidated revenue of 604.3 billion won and an operating profit of 33.2 billion won for the third quarter. These figures represent increases of 6.0% and 50.5%, respectively, compared to the same period last year.
By business segment, the pharmaceutical division led earnings growth. Third-quarter pharmaceutical revenue reached 378 billion won, up 4.8% from the same period last year. Healthcare business revenue also increased by 32.7% to 69.2 billion won, contributing to overall expansion.
License (rights) revenue from technology exports and other sources also expanded. Third-quarter license revenue was 7.9 billion won, an increase of 82.5% over the same period last year. Coupled with increased pharmaceutical sales and higher royalty income, the company recorded operating profit growth that exceeded its revenue growth rate.
A Yuhan official stated, "As global commercialization of the Leqembi combination therapy continues to expand, royalties from global sales have become a key revenue source driving performance alongside existing businesses."
The official added, "Based on Leqembi's global success, we will continue R&D investment for the development of second and third-generation Leqembi-like drugs, strengthening a virtuous cycle of innovative drug creation."
in THEBIO
